We are live on ! Find out more
KCM

Kynam Capital Management Portfolio holdings

AUM $1.62B
1-Year Est. Return 138.67%
This Fund
S&P 500
This Quarter Est. Return
-11.7%
1 Year Est. Return
+138.67%
3 Year Est. Return
+268.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$308M
AUM Growth
+$121M
Cap. Flow
+$155M
Cap. Flow %
50.3%
Top 10 Hldgs %
76.16%
Holding
37
New
5
Increased
13
Reduced
15
Closed
4

Top Buys

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$58.1M
2
TVTX icon
Travere Therapeutics
TVTX
+$18.3M
3
CLDX icon
Celldex Therapeutics
CLDX
+$16.8M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$16.4M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$10.4M

Top Sells

Rank Stock Value
1
XENE icon
Xenon Pharmaceuticals
XENE
+$5.59M
2
ZGNX
Zogenix, Inc.
ZGNX
+$3.34M
3
LQDA icon
Liquidia Corp
LQDA
+$1.3M
4
COGT icon
Cogent Biosciences
COGT
+$1.29M
5
KRYS icon
Krystal Biotech
KRYS
+$1.03M

Sector Composition

Rank Sector Weight
1 Healthcare 99.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GBT
1
DELISTED
Global Blood Therapeutics, Inc.
GBT
$46.4M 15.05%
1,339,322
+346,373
+35% +$10.4M
NTRA icon
2
Natera
NTRA
$37.5B
$39.3M 12.75%
+966,400
New +$58.1M
SNDX icon
3
Syndax Pharmaceuticals
SNDX
$1.84B
$33.6M 10.9%
1,932,800
+976,635
+102% +$16.4M
CLDX icon
4
Celldex Therapeutics
CLDX
$2.77B
$25.6M 8.32%
753,034
+526,308
+232% +$16.8M
TVTX icon
5
Travere Therapeutics
TVTX
$5.33B
$22.4M 7.28%
870,918
+688,815
+378% +$18.3M
GOSS icon
6
Gossamer Bio
GOSS
$66.5M
$15.9M 5.16%
1,832,704
+815,847
+80% +$7.87M
XENE icon
7
Xenon Pharmaceuticals
XENE
$6.32B
$14.8M 4.79%
483,270
-186,823
-28% -$5.59M
PCVX icon
8
Vaxcyte
PCVX
$7.89B
$14M 4.54%
579,640
+368,157
+174% +$8.04M
VERA icon
9
Vera Therapeutics
VERA
$2.54B
$11.8M 3.83%
502,328
+248,879
+98% +$5.35M
VRDN icon
10
Viridian Therapeutics
VRDN
$2.13B
$10.9M 3.54%
589,826
+301,892
+105% +$5.8M
LQDA icon
11
Liquidia Corp
LQDA
$7.67B
$8.33M 2.7%
1,159,674
-207,162
-15% -$1.3M
BIIB icon
12
Biogen
BIIB
$29.9B
$8.05M 2.61%
38,236
-1,764
-4% -$384K
AMRN
13
Amarin Corp
AMRN
$284M
$7.55M 2.45%
114,704
+4,161
+4% +$275K
BNR
14
Burning Rock Biotech
BNR
$94.4M
$7.18M 2.33%
77,311
+39,065
+102% +$3.39M
SRRA
15
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$6.2M 2.01%
+193,280
New +$5.55M
CNTA
16
DELISTED
Centessa Pharmaceuticals
CNTA
$6M 1.95%
669,100
+430,059
+180% +$3.92M
FOLD
17
DELISTED
Amicus Therapeutics
FOLD
$5.43M 1.76%
573,516
-183
-0% -$1.72K
WVE icon
18
Wave Life Sciences
WVE
$1.12B
$3.82M 1.24%
1,911,728
+417,134
+28% +$1.02M
FATE icon
19
Fate Therapeutics
FATE
$281M
$3.54M 1.15%
91,337
-4,224
-4% -$164K
MRUS
20
DELISTED
Merus
MRUS
$3.09M 1%
116,764
-5,394
-4% -$145K
MCRB icon
21
Seres Therapeutics
MCRB
$48M
$2.08M 0.67%
14,572
-673
-4% -$104K
PBYI icon
22
Puma Biotechnology
PBYI
$406M
$1.88M 0.61%
653,445
-30,174
-4% -$78K
AKUS
23
DELISTED
Akouos Inc
AKUS
$1.84M 0.6%
387,892
+288,884
+292% +$1.69M
RDUS
24
DELISTED
Radius Health, Inc.
RDUS
$1.64M 0.53%
185,514
-8,568
-4% -$65K
AFMD
25
DELISTED
Affimed
AFMD
$1.52M 0.49%
34,797
-1,606
-4% -$69.8K
1
2

Similar funds

IPW
Invictus Private Wealth Denver, Colorado $1.62B AUM 22.63% 1-Year Est. Return
WIC
Woodmont Investment Counsel Nashville, Tennessee $1.62B AUM 18.92% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
TLFA
True Link Financial Advisors San Francisco, California $1.62B AUM 8.33% 1-Year Est. Return
KCM
Kathmere Capital Management Wayne, Pennsylvania $1.62B AUM 17.7% 1-Year Est. Return
PRA
Pine Ridge Advisers New York $1.62B AUM 16.97% 1-Year Est. Return
BW
Browning West Los Angeles, California $1.62B AUM 22.28% 1-Year Est. Return
CC
Covalis Capital London, United Kingdom $1.63B AUM 27.84% 1-Year Est. Return

Kynam Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, Kynam Capital Management held 37 positions worth $308M, up 65% from $187M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Kynam Capital Management deployed $155M of net new capital in Q1 2022, opening 5 new positions and adding to 13 existing holdings. Its largest new stake was Natera: 966,400 shares worth $39.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier.

On the sell side, the largest reduction was Xenon Pharmaceuticals, an estimated $5.59M trimmed.

  • Kynam Capital Management's largest Q1 2022 buy was Natera: 966,400 shares worth $39.3M.
  • Kynam Capital Management added most to Travere Therapeutics in Q1 2022, an estimated $18.3M increase.
  • Kynam Capital Management's biggest Q1 2022 reduction was Xenon Pharmaceuticals, cutting an estimated $5.59M.
  • Kynam Capital Management fully exited Zogenix, Inc. in Q1 2022, selling an estimated $3.34M.
  • Kynam Capital Management's ten largest holdings make up 76% of its $308M portfolio in Q1 2022.
  • Kynam Capital Management opened 5 new positions and closed 4 in Q1 2022.
  • Kynam Capital Management's portfolio value rose 65% quarter-over-quarter to $308M.

Based on Kynam Capital Management's 13F filing for Q1 2022, filed 13 May 2022.